Related Experiment Video
Updated: Sep 20, 2025

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
Published on: May 24, 2024
Recent Pathophysiological Insights Are Advancing the Treatment of Venous Thromboembolism
Satish Singh1, Pardeep Kumar2, Sudesh K Yadav2
1CSIR-Institute of Himalayan Bioresource Technology, Palampur, Himachal Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India; Translational Cardiovascular Research Center, Department of Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.
Insights
Venous thromboembolism (VTE) causes significant cardiovascular deaths. This review explores thrombus aging mechanisms and novel pharmacotherapeutic strategies for VTE, aiming for improved safety and efficacy.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, is a major cause of cardiovascular mortality.
- Unresolved venous thrombi can lead to chronic complications like post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension.
- Aging thrombi develop fibrotic changes, rendering them unresponsive to current treatments.
Purpose of the Study:
- To review the mechanisms of venous thrombus aging.
- To discuss the clinical implications of thrombus aging.
- To present the latest pharmacotherapeutic developments for VTE.
Main Methods:
- Literature review of venous thrombus aging.
- Analysis of current and emerging VTE pharmacotherapies.
- Discussion of therapeutic strategies targeting acute and transition phases of VTE.
Main Results:
- Venous thrombus composition evolves from acute to chronic, fibrotic states.
- Standard anticoagulation has limitations in preventing recurrence and carries bleeding risks.
- Novel drug discovery targets acute VTE, while anti-inflammatory agents, statins, and vasodilators are explored for the acute-to-chronic transition.
Conclusions:
- Understanding thrombus aging is crucial for developing effective VTE treatments.
- Emerging pharmacotherapies offer potential for enhanced safety and efficacy in VTE management.
- Targeting different stages of VTE, from acute to chronic, is key to improving patient outcomes.
Abstract:
Venous thromboembolism, defined as deep vein thrombosis and pulmonary embolism, is the third leading cause of cardiovascular deaths globally. Long-term complications of unresolved venous thrombi include post-thrombotic syndrome in the legs and chronic thromboembolic pulmonary hypertension. As the venous thrombus ages, the acute, fibrin, and red blood cell-rich composition changes to a chronic cellular, fibrotic mass that does not respond to presently available therapeutic approaches. Standard anticoagulation treatment does not fully prevent recurrent thrombosis and may cause serious bleeding. Thrombolytic therapy may resolve thrombi but it has unacceptable bleeding risks. Recent drug discovery for acute venous thromboembolism has focused on novel targets that may provide enhanced safety and efficacy. Additional therapeutic strategies have focused on the transition phase of acute-to-chronic venous thromboembolism with anti-inflammatory agents, statins, and vasodilator drugs. In this review, we discuss the mechanisms of venous thrombus aging, its clinical implications, and the latest developments in pharmacotherapeutic approaches for venous thromboembolism.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Return
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
Varicose Veins II: Diagnostic Studies and Interprofessional Care

